Eli Lilly and Company announced today a major partnership with NVIDIA to launch a first-of-its-kind AI co-innovation lab designed to take on some of the pharmaceutical industry’s hardest problems. The collaboration will see the two companies...
AbbVie and RemeGen have entered into an exclusive global licensing agreement to develop and commercialise RC148, an investigational bispecific antibody for cancer treatment. Under the agreement, AbbVie will hold rights to RC148 outside Greater Ch...
.jpeg)
Aragen launches CHOMax, a cell line and early manufacturing platform, taking monoclonal antibody programmes from DNA to IND-enabling clinical supply in 10 months.
.png)
Lupin Limited has signed an exclusive license, supply, and distribution agreement to commercialize Bofanglutide in India, marking a major step in the battle against type 2 diabetes and obesity. Under the pact with China’s Gan&Lee Pharmaceuticals...
Merck & Co. has initiated KANDLELIT-007, a global Phase 3 clinical trial evaluating its investigational oral KRAS G12C inhibitor calderasib (MK-1084) in combination with KEYTRUDA QLEX™, a subcutaneous formulation of pembrolizumab with berahyalur...
Eli Lilly’s Zepbound-Taltz combination has delivered strong results in a late-stage clinical trial, showing improved arthritis relief alongside meaningful weight loss, reinforcing the growing link between obesity management and inflammatory dis...
Shilpa Medicare Limited is preparing to seek US approval for its Ondansetron Extended-Release Injection (OERIS) within the next two years and is actively exploring licensing partners. The decision follows a successful Phase 3 trial in India, with..
Granules India announced today that U.S. based company, Granules Pharmaceuticals, Inc., has gotten probable designation of the U.S. Food and Drug Administration (FDA) on its generic amphetamine prolonged discharge pills that treat attention...
Biocon Ltd announced Tuesday that its unit Biocon Biologics oncology biosimilars will expand with three new cancer therapies aimed at strengthening its presence in the global oncology market. With a regulatory filing, the company announced that...
Lupin Ltd announced today that its subsidiary, Lupin Manufacturing Solutions has entered into a longterm agreement with PolyPeptide Group AG. The joint venture will strengthen the global peptide-based active pharmaceutical ingredients supply...
.jpg)
.jpg)
, CDSCO.jpg)